Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00346658 · ClinicalTrials.gov registry record · Phase 1
Magnesium Supplementation to Prevent Bone Loss
A Phase 1 study, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT00346658 is a Phase 1 study that has completed, run by University of Tennessee. The registered enrollment target is 74 participants.
The verdict
NCT00346658, a Phase 1 study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
Extreme magnesium deficiency is known to have an impact on the synthesis, secretion and/or action of calcium regulating hormones. Many older adults are at risk for less severe magnesium deficiency, since the majority of adults receive less than the Recommended Daily Allowance of magnesium. We hypothesize that magnesium supplementation will have a beneficial effect on calcium regulating hormones and markers of bone turnover.
Interventions
- DRUG magnesium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2002-07 |
| Est. Completion | 2006-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00346658
The ClinicalTrials.gov registry entry for NCT00346658 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Tennessee, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which magnesium is the first listed.
NCT00346658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00346658 about?
NCT00346658 is a clinical study titled "Magnesium Supplementation to Prevent Bone Loss". Extreme magnesium deficiency is known to have an impact on the synthesis, secretion and/or action of calcium regulating hormones. Many older adults are at risk for less severe magnesium deficiency, since the majority of adults receive less than the Recommended Daily Allowance of magnesium. We hypoth...
What is the current status of trial NCT00346658?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2002-07. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00346658?
The interventions under investigation include: magnesium (DRUG).
Who is sponsoring clinical trial NCT00346658?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.